Proceeds from the financing will allow Karius to expand access to its proprietary microbial cell-free DNA technology, as well as advance clinical development, and accelerate innovation.
Poor infiltration of the tumor by immune cells, low activity from available T cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to hinder response to immunotherapy.
The FDA believes it has sufficient scientific evidence to suggest certain genetic variants are likely to have altered the metabolism of many drugs, and in certain cases, result in different therapeutic results, including a difference in risk of adverse events.
The test uses the company’s CoPrimer technology to detect the presence of ribonucleic acid (RNA) of the novel strain of coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome.
A newly discovered pathway that detects DNA in the cytoplasm and triggers inflammation and cellular senescence, may be modulated during senescence-inducing chemotherapy to affect cancer cell response to checkpoint inhibitors.
The researchers used single cell technology to isolate and analyze around 200,000 individual cells from the developing thymus to record which genes were active in each individual cell and used those genes as tags to map each cell to its exact location in the thymus.
Precision Molecular Nabs Investment from ADDF for Development of More Effective Neuroinflammation Imaging Agents
The company’s radiotracer, PMI04, binds the macrophage colony stimulating factor 1 receptor (CSF1R) which, in the brain, is found almost exclusively on microglia and infiltrating macrophages, cell types directly involved in inflammation.
The chaperone protein Clusterin shuttles misfolded proteins directly into cells for degradation, a finding that could point to new therapeutic targets for AD and other neurodegenerative diseases.
MammaPrint and BluePrint reclassified 40% of pathologically subtyped tumors, highlighting the need for an individualized, molecular subtyping profile in early stage breast cancer diagnosing for patients.
The maps detail the intricacies and complexity of the breast cancer landscape—comprising cancer cells, immune cells and connective tissue—and how it varies both between, and within, tumors depending on their unique genetic makeup.